Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Phase 1 × Terminated × Fatigue × Clear all

Phase

Phase NA 16 Phase 2 9 Phase 3 3 Phase 2/3 3 Phase EARLY_PHASE1 1 Phase 1 1

Status

Completed 7 Withdrawn 1 Terminated 1

Sponsor Class

Study Type

Interventional 1

Sponsor

Conditions

Neoplasms 236 Carcinoma, Non-Small-Cell Lung 205 Leukemia, Myeloid, Acute 164 Breast Neoplasms 128 Melanoma 123 Neoplasm Metastasis 115 Multiple Myeloma 104 Recurrence 97 Lymphoma 95 Colorectal Neoplasms 95 Lymphoma, Non-Hodgkin 94 Leukemia, Lymphocytic, Chronic, B-Cell 88 Pancreatic Neoplasms 84 Ovarian Neoplasms 83 Precursor Cell Lymphoblastic Leukemia-Lymphoma 77 Leukemia 75 Prostatic Neoplasms 68 Lung Neoplasms 68 Lymphoma, Large B-Cell, Diffuse 64 Glioblastoma 62 Carcinoma, Renal Cell 61 Squamous Cell Carcinoma of Head and Neck 60 Myelodysplastic Syndromes 55 Lymphoma, Follicular 54 Brain Neoplasms 50 Sarcoma 47 Lymphoma, Mantle-Cell 45 Stomach Neoplasms 41 Head and Neck Neoplasms 40 Glioma 39

Interventions

Methylphenidate 1 5,10-dihydro-5-methylphenazine 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT01164956 2019-04-26

Methylphenidate for Cancer-Related Fatigue

Dana-Farber Cancer Institute

Phase 1 Terminated

3 enrolled 7 charts

Fatigue, Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon ⚡